A double-blind randomized clinical trial comparing the safety and antiviral activity of 48-week clevudine and adefovir-dipivoxil in HBeAg(-) [hepatitis e antigen negative] chronic hepatitis b with compensated liver function.

Trial Profile

A double-blind randomized clinical trial comparing the safety and antiviral activity of 48-week clevudine and adefovir-dipivoxil in HBeAg(-) [hepatitis e antigen negative] chronic hepatitis b with compensated liver function.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2012

At a glance

  • Drugs Adefovir dipivoxil; Clevudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Bukwang Pharmaceutical
  • Most Recent Events

    • 24 Apr 2012 Actual patient number is 43 according to ClinicalTrials.gov.
    • 24 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top